Our Technology
Corporate Presentation
Presentations and Publications
Pipeline
HPV-Associated Cancers
PSA-Associated Cancers
HER2-Associated Cancers
NEO Program
HOT Program
Patient Stories
Partners
About Us
Investors
Our Technology
Corporate Presentation
Presentations and Publications
Pipeline
HPV-Associated Cancers
PSA-Associated Cancers
HER2-Associated Cancers
NEO Program
HOT Program
Patient Stories
Partners
About Us
Investors
Presentations & Publications
Back
Presentation
Back
Presentation
Targeting frameshift mutations with a Listeria monocytogenes immunotherapy drives neoantigen-specific anti-tumor immunity in the MC38 and CT26 mouse tumor models
AACR 2018
ADXS-NEO Lm-Frameshift muations AACR poster_Final
STAY TUNED
Mailing List
Sign up for email alerts for Press Releases & breaking Advaxis news.
SOCIAL
Follow Us
Stay up to date on the latest events, news, and happenings on Advaxis and Immunotherapy.
